Fernando Galán Galán
Profesor Titular de Medicina
Especialista en Medicina Interna
Experto en Miopatía Mitocondrial del Adulto
Fibromialgía y Síndrome de Fatiga crónica
Fernando Galán Galán Fernando Galán Galán Fernando Galán Galán Fernando Galán Galán

954 286 206 - 639 231 348
galanfernando361@gmail.com

Curriculum Vitae

  • FORMACIÓN ACADÉMICA +

  • DATOS PROFESIONALES +

  • LÍNEAS DE INVESTIGACIÓN O DESARROLLO EN QUE HA TRABAJADO +

  • PARTICIPACIÓN EN PROYECTOS DE INVESTIGACIÓN FINANCIADOS +

  • PUBLICACIONES +

  • CAPÍTULOS DE LIBROS +

  • TESIS DOCTORALES DIRIGIDAS +

  • TÉCNICAS O ESPECIALIDADES QUE DOMINA +

  • Critical role of AMP-activated protein kinase in the balance between mitophagy and mitochondrial biogenesis in MELAS disease. +

  • Mitochondrial myopathy in follow up a patient with chronic fatigue syndrome +

    Fernando Galán, Isabel de Lavera, David Cotán, José A. Sánchez-Alcázar.

    Journal of Investigative Medicine High Impact Case Reports July-September 2015

    Read More
  • 1

Burnout, depression and suicidal ideation in dental students. F Galán, J-V Ríos-Santos, J Polo, B Rios-Carrasco, P Bullón. Medicina oral, patologia oral y cirugia bucal (Impact Factor: 1.1). 10/2013; 19(3). DOI: 10.4317/medoral.19281

Serum 25-hydroxyvitamin D in early autumn to ensure vitamin D sufficiency in mid-winter in professional football players Fernando Galan, Juan Ribas, Pilar María Sánchez-Martinez, Tomás Calero, Antonio Barco Sánchez, Adolfo Muñoz. Clinical nutrition (Edinburgh, Scotland) 08/2011; 31(1):132-6. · 3.27

Burnout risk in medical students in Spain using the Maslach Burnout Inventory-Student Survey. Fernando Galán, Arturo Sanmartín, Juan Polo, Lucas Giner. International Archives of Occupational and Environmental Health 03/2011; 84(4):453-9. · 2.10 Impact Factor

Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. European Prospective Osteoporosis Study. P Vergnaud, M Lunt, C Scheidt-Nave, G Poor, C Gennari, K Hoszowski, A Lopes Vaz, D M Reid, L Benevolenskaya, S Grazio, K Weber, T Miazgowski, J J Stepan, P Masaryk, F Galan, J Bruges Armas, R Lorenc, S Havelka, R Perez Cano, M Seibel, G Armbrecht, S Kaptoge, T W O'Neill, A J Silman, D Felsenberg, J Reeve, P D Delmas . Clinica Chimica Acta 08/2002; 322(1-2):121-32. · 2.76 Impact Factor

Dual X-ray absorptiometry—cross-calibration and normative reference ranges for the spine: Results of a European Community Concerted Action. J. Dequeker, J. Pearson, J. Reeve, M. Henley, J. Bright, D. Felsenberg, W. Kalender, A-M. Laval-Jeantet, P. Ruegsegger, J. Adams, M. Diaz Curiel, M. Fischer, F. Galan, P. Geusens, L. Hyldstrup, P. Jaeger, P. Kotzki, H. Kröger, P. Lips, A. Mitchell, O. Louis, R. Perez Cano, H. Pols, D.M. Reid, C. Ribot, P. Schneider, M. Lunt. Bone 09/1995; 17(3):247–254. · 4.46 Impact Factor

European semi-anthropomorphic spine phantom for the calibration of bone densitometers: Assessment of precision, stability and accuracy the European quantitation of osteoporosis study group. J. Pearson, J. Dequeker, M. Henley, J. Bright, J. Reeve, W. Kalender, A. M. Laval-Jeantet, P. Rüegsegger, D. Felsenberg, J. Adams, J. C. Birkenhäger, P. Braillon, M. Diaz Curiel, M. Fischer, F. Galan, P. Geusens, L. Hyldstrup, P. Jaeger, R. Jonson, J. Kalef-Ezras, P. Kotzki, H. Kröger, A. Lingen, S. Nilsson,M. Osteaux, R. Perez Cano, D. M. Reid, C. Reiners, C. Ribot, P. Schneider, D. O. Slosman, G. Wittenberg. Osteoporosis International 04/1995; 5(3):174-184. · 4.17 Impact Factor

Dual X-ray absorptiometry of the proximal femur: Normal european values standardized with the european spine phantom. J. Pearson, J. Dequeker, J. Reeve, D. Felsenberg, M. Henley, J. Bright, M. Lunt, J. Adams, Diaz M. Curiel, F. Galan, [......], A. Mitchell, Perez R. Cano, H. Pols, A. Rapado, D.M. Reid, C. Ribot, P. Schneider, A.M. Laval‐Jeantet, P. Ruegsegger, W. Kalender . Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 02/1995; 10(2). 315-24· 6.04 Impact Factor

Risk factors for hip fracture in pish and Turkish women. R Perez Cano, F Galan Galan, G Dilsen. Bone 02/1993; 14 Suppl 1:S69-72. · 4.46 Impact Factor

[Changes in the glycolytic pathway in patients with essential arterial hypertension]. R Pérez Cano, C Murillo del Castillo, R Moruno García, J Oliván Martínez, M Montoya García, F Galan Galán, M Garrido Peralta. Anales de medicina interna (Madrid, Spain: 1984) 06/1990; 7(5):233-6.

[Intraerythrocyte levels of glucose-6-phosphate dehydrogenase in patients with essential arterial hypertension and persons with normal blood pressure. Modifications after nifedipine therapy]. R Pérez Cano, C Murillo del Castillo, M J Montoya García, J Olivan Martínez, R Moruno García, F Galán Galán, M Garrido Peralta. Anales de medicina interna (Madrid, Spain: 1984) 05/1990; 7(4):174-7.

Calcitonin reserve in healthy women and patients with postmenopausal osteoporosis. R Pérez Cano, M J Montoya, R Moruno, A Vazquez, F Galan, M Garrido. Calcified Tissue International 11/1989; 45(4):203-8. · 2.75 Impact Factor

ADFR therapy in the prevention of bone loss after menopause. R Pérez Cano, R Moruno, M J Montoya, M A Vazquez, F Galán, M Garrido. Clinical Rheumatology 07/1989; 8 Suppl 2:56-60. · 1.77 Impact Factor

[Extracellular metabolism of calcium in essential arterial hypertension. Relation to the functional status of the renin axis]. J M Mellado, R Pérez Cano, J Oliván, J López Chozas, A Jiménez, F Galán, M Garrido Peralta. Medicina Clínica 04/1986; 86(12):494-7. · 1.25 Impact Factor

[Changes in serum levels of ionic calcium during the treatment of hypertensive emergencies with nifedipine]. R Pérez Cano, C Murillo, J Oliván, F Galán, M J Montoya, M Garrido. Medicina Clínica 11/1985; 85(10):404-8. · 1.25 Impact Factor

[Calcitonin deficiency in postmenopausal osteoporosis]. F Galán Galán, R Pérez Cano, R Rodríguez, B Vargas, A Jiménez Rubio-Manzanares, O Aramburu Bodas, M Garrido Peralta. Medicina Clínica 08/1985; 85(6):221-4. · 1.25 Impact Factor

[Changes in calcium metabolism in patients with renal lithiasis]. M Montaño Díaz, R Pérez Cano, F Galán Galán, O Aramburu Bodas, A Jiménez Rubio-Manzanares, F Navarro Sarabia, M Garrido Peralta. Medicina Clínica 05/1985; 84(13):512-5. · 1.25 Impact Factor

[Circadian rhythm of ionic calcium. Influence of specimen handling on serum levels]. M A Vázquez Gámez, R Pérez Cano, F Galán Galán, M Garrido Peralta. Medicina Clínica 03/1985; 84(6):223-6. · 1.25 Impact Factor

[Immunologic and ultrastructural study of a non-secretor IgG multiple myeloma]. F Galán Galán, R Pérez Cano, F Carrasco Díaz, A Hevias Vázquez, F Malagón Cobo, A Benítez Domínguez, O Aramburu Bodas, M Garrido Peralta. Revista Clínica Española 02/1985; 176(1):46-8. · 1.31 Impact Factor

[Status of metabolic abnormalities in nephrolithiasis]. M Montaño Díaz, R Pérez Cano, F Galán Galán, O Aramburu Bodas, A Jiménez Rubio-Manzanares. Medicina Clínica 01/1985; 83(18):780. · 1.25 Impact Factor

Is there an extrathyroidal source of calcitonin during pregnancy? F Galán Galán, F C Balbontin, R P Cano, A J Rubio, M G Añon, M G Peralta. Acta endocrinologica 03/1984; 105(2):266-70.

High plasma calcitonin concentrations in chronic bronchitis. F G Galan, J Hurtado, R P Cano, M G Peralta British medical journal (Clinical research ed.) 10/1982; 285(6345):850-1.

[Calcitonin as a tumor marker. II. Calcitonin in non-thyroid tumors]. F Galán Galán, M Garrido Peralta. Revista Clínica Española 05/1982; 165(2):73-6. · 1.31 Impact Factor

[Calcitonin as a tumor marker. I. Medullary carcinoma of the thyroid]. F Galán Galán, M Garrido Peralta. Revista Clínica Española 05/1982; 165(1):5-9. · 1.31 Impact Factor

[Calcitonin in 1981. A hormone in search of a function?]. F Galán Galán, M Garrido Peralta. Revista Clínica Española 04/1982; 164(6):353-7. · 1.31 Impact Factor

Identification of both human and salmon calcitonin-like molecules in birds suggesting the existence of two calcitonin genes. R Perez Cano, S I Girgis, F Galan Galan, I MacIntyre. Journal of Endocrinology 04/1982; 92(3):351-5. · 3.59 Impact Factor

The lung is the major organ source of calcitonin in the lizard. M Ravazzola, L Orci, S I Girgis, F Galan Galan, I McIntyre. Cell Biology International Reports 11/1981; 5(10):937-44.

A human calcitonin-like molecule in the ultimobranchial body of the amphibia (Rana pipiens). R Perez-Cano, F Galan Galan, S I Girgis, T R Arnett, I MacIntyre. Experientia 11/1981; 37(10):1116-8.

Immunochemical characterization and distribution of calcitonin in the lizard. F Galan Galan, R M Rogers, S I Girgis, T R Arnett, M Ravazzola, L Orci, I MacIntyre. Acta endocrinologica 08/1981; 97(3):427-32.

Immunoreactive calcitonin in the central nervous system of the pigeon. F Galan Galan, R M Rogers, S I Girgis, I MacIntyre. Brain Research 06/1981; 212(1):59-66. · 2.83 Impact Factor

Immunoreactive human calcitonin-like molecule in the nervous systems of protochordates and a cyclostome, Myxine. S I Girgis, F. Galan Galan, T R Arnett, R M Rogers, Q Bone, M Ravazzola, I MacIntyre. Journal of Endocrinology 01/1981; 87(3):375-82. · 3.59 Impact Factor

[Free fatty acids and arrhythmia in acute myocardial infarct. Gas chromatography]. M A Muniain Ezcurra, J Venero Gómez, R Pérez-Cano, J Rodriguez-Piñero, F Galán Galán, M Garrido Peralta. Revista Clínica Española 10/1979; 154(5):179-82. · 1.31 Impact Factor

[Serum activity of betaglucuronidase in chemical diabetes]. J M Araquistain, F Galán, J Jiménez Pereperez, R Pérez Cano, J Venero, J Herrerias, M Garrido. Revista Clínica Española 01/1978; 147(6):593-5. · 1.31 Impact Factor

[Study of serum levels of betaglucuronidase in arteriosclerotic patients]. F Galán, J Jiménez Perepérez, J M Araquistain, R Pérez Cano, M A Muniain, M Garrido. Revista Clínica Española 01/1978; 147(5):503-5. · 1.31 Impact Factor

[Malignant histiocytic medullary reticulosis]. E de Justo y Alpañes, M A Ruilópez, I Ortega Medina, R Pérez Cano, F Galán, A Matilla, M Garrido Peralta. Revista Clínica Española 11/1977; 147(2):211-5. · 1.31 Impact Factor

[Unusual form of ischemic colitis]. J Herrerias, F Galán, A Morales, T Alvarez, J Rodriguez Piñero, R Perez Cano, M Garrido Peralta. Revista española de las enfermedades del aparato digestivo 03/1977; 49(3):417-24.

AMPK as a target in rare diseases. David Cotán, Marina Villanueva Paz, Elizabet Alcocer-Gómez, Juan Garrido-Maraver, Manuel Oropesa-Ávila, Mario de la Mata, Ana Delgado Pavón, Isabel de Lavera, Fernando Galán, Patricia Ybot-González, José A. Sánchez-Alcázar. Current Drug Targets 02/2015; · 3.60 Impact Factor

ORCI

0000-0002-2130-9897

CONSULTAME